ANAL FISSURE TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Anal fissure is a common medical condition that affects a significant number of individuals worldwide. It refers to a small tear or cut in the lining of the anus, resulting in discomfort, pain, and sometimes bleeding during bowel movements. While anal fissures can heal on their own, it often require treatment to alleviate symptoms and promote healing.

Many anal fissures heal by themselves in a few weeks, but complications can develop when they don’t. These are called chronic anal fissures. Instead of healing, they continue to reinforce themselves in a vicious cycle, leaving a persistent wound.

Symptoms of anal fissure includes; Pain during bowel movements, Pain after bowel movements that can last up to several hours, Bright red blood on the stool or toilet paper after a bowel movement, a visible crack in the skin around the anus, a small lump or skin tag on the skin near the anal fissure

Global anal fissure treatment market is witnessing significant growth due to increasing prevalence of anal fissures globally. Factors such as sedentary lifestyles, poor dietary habits, and rising aging population contribute to growing incidence of anal fissures. Rising awareness about the availability of various treatment options and increasing demand for minimally invasive procedures are further driving the market growth.

Market Dynamics:

Increasing prevalence of anal fissure globally and increasing product launches by the market players are expected to aid drive the market growth over the forecast period. For instance, on September 15, 2022, according to the data published by the Clinical Medicine, annual incidence of anal fissures in the general population is 0.11% in New Mexico.

Key Features of the Study:

• This study provides a comprehensive analysis of the global anal fissure treatment market, including market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period of 2023-2030, with 2022 as the base year
• The report elucidates potential revenue opportunities across different segments and offers attractive investment proposition matrices for this market
• It provides key insights into market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• The profiles of key players in the global anal fissure treatment market are included, highlighting their company background, product portfolio, financial performance, and strategies
• Key companies covered in this study include Abvie, Novartis AG, Teva Pharmaceuticals, Troikaa, RDD Pharma, Ltd, Kyowa Kirin Co., Ltd, Cipla Inc., Ipsen Pharma, Sanofi, Boehringer Ingelheim International GmbH, Bliss GVS, SRS Life Sciences, Healthy Life Pharma Private Limited, and Geri-Care Pharmaceuticals Corp
• The insights from this report enable marketers and management authorities of companies to make informed decisions regarding product launches, market expansion, and marketing tactics
• Global anal fissure treatment market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders can make informed decisions through different strategy matrices used in analyzing the global anal fissure treatment market

Anal Fissure Treatment Market Detailed Segmentation:

• By Treatment Type
  • Laxatives
  • Topical Nitrates
  • Calcium Channel Blockers
  • Stool Softeners
  • Surgery
  • Others
• By Route of Administration
  • Oral
  • Topical
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Top companies in Global Anal Fissure Treatment Market
  • Abvie
  • Novartis AG
  • Teva Pharmaceuticals
  • Troikaa
  • RDD Pharma, Ltd
  • Kyowa Kirin Co., Ltd
  • Cipla Inc.
  • Ipsen Pharma
  • Sanofi
  • Boehringer Ingelheim International GmbH.
  • Bliss GVS
  • SRS Life Sciences
  • Healthy Life Pharma Private Limited
  • Geri-Care Pharmaceuticals Corp.